FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

The U.S. Food and Drug Administration has approved MIMRYLO, also known as rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera, a rare and chronic blood cancer.

The decision introduces the first hepcidin mimetic medicine authorized for this condition, offering patients a new mechanism of action beyond the therapies currently available.

A Long-Standing Challenge in PV Management

Polycythemia vera affects an estimated 90,000 people in the United States. The disease causes the bone marrow to produce too many red blood cells, raising hematocrit levels and increasing blood thickness.

This buildup can lead to serious complications, including stroke, deep vein thrombosis, and pulmonary embolism. Keeping hematocrit consistently below 45% remains the primary treatment goal, since uncontrolled hematocrit is linked to a fourfold higher risk of cardiovascular death or major cardiovascular events.

Despite existing treatments such as phlebotomy and cytoreductive therapy, an estimated 78% of patients continue to experience uncontrolled hematocrit. Many also live with persistent symptoms, including fatigue, itching, difficulty concentrating, and night sweats.

How MIMRYLO Works

MIMRYLO mimics hepcidin, a hormone that naturally regulates how the body distributes iron. By restoring more balanced iron regulation, the medicine aims to limit the bone marrow’s overproduction of red blood cells.

This mechanism is intended to help patients maintain hematocrit control without relying solely on frequent blood removal procedures. MIMRYLO is administered through a subcutaneous injection once each week.

VERIFY Trial Supported the Approval

The FDA approval was based on results from the global, randomized, placebo-controlled Phase 3 VERIFY study, which enrolled 293 patients with polycythemia vera who had uncontrolled hematocrit and were dependent on phlebotomy despite receiving standard treatment.

The trial’s primary goal was to measure the proportion of patients who achieved a clinical response between Weeks 20 and 32, defined as no longer meeting the criteria for phlebotomy eligibility.

Among patients treated with MIMRYLO alongside standard care, 76.9% achieved this primary response, compared with 32.9% of those receiving placebo plus standard care. MIMRYLO met all four key secondary endpoints in the study.

Long-Term Results Through 52 Weeks

The trial included an extension period allowing researchers to evaluate how well the treatment response held up over time.

By Week 52, 61.9% of patients receiving MIMRYLO throughout the study experienced a durable clinical response, meaning they consistently avoided phlebotomy eligibility.

Among patients who responded during the initial assessment window, 84.1% maintained that response through the following weeks. Patients who switched from placebo to MIMRYLO also showed strong results, with 77.9% achieving a clinical response after starting active treatment.

The median time before a patient needed their first phlebotomy was 16 weeks in the placebo group. Among those treated with MIMRYLO, the median time to first phlebotomy was not reached during the study period, reflecting a longer duration of hematocrit control.

Average hematocrit remained below 43% through Week 52 in patients treated with MIMRYLO, including those who began the medicine partway through the study after starting on placebo.

Improvements in Fatigue and Quality of Life

Because fatigue is one of the most burdensome symptoms of polycythemia vera, the study also tracked patient-reported outcomes using established fatigue and symptom assessment tools.

Patients treated with MIMRYLO maintained improvements in fatigue scores throughout the study, suggesting that better hematocrit control may also translate into a meaningful difference in daily quality of life.

What This Means for Patients

For many people living with polycythemia vera, frequent phlebotomy has long been the primary method for controlling hematocrit, despite its inconvenience and limited ability to address the disease’s underlying biology.

MIMRYLO’s approval offers an additional treatment option designed to work through a different biological pathway, potentially reducing the need for repeated blood removal procedures while helping patients maintain more stable hematocrit levels over time.

Takeda said the medicine is expected to become available to patients within a short window following FDA approval, reflecting the priority review status granted during the regulatory process.